AnaptysBio Inc. (ANAB) and Evelo Biosciences Inc. (NASDAQ:EVLO) Contrasting side by side

AnaptysBio Inc. (NASDAQ:ANAB) and Evelo Biosciences Inc. (NASDAQ:EVLO) compete against each other in the Biotechnology sector. We will compare them and contrast their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AnaptysBio Inc. 5.00M 397.41 68.65M -2.68 0.00
Evelo Biosciences Inc. N/A 0.00 68.27M -2.14 0.00

Demonstrates AnaptysBio Inc. and Evelo Biosciences Inc. earnings per share (EPS), gross revenue and valuation.


Table 2 provides us AnaptysBio Inc. and Evelo Biosciences Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
AnaptysBio Inc. -1,373.00% -15.8% -15%
Evelo Biosciences Inc. 0.00% -47.8% -41%


The current Quick Ratio of AnaptysBio Inc. is 17 while its Current Ratio is 17. Meanwhile, Evelo Biosciences Inc. has a Current Ratio of 11.9 while its Quick Ratio is 11.9. AnaptysBio Inc. is better positioned to pay off its short-term and long-term debts than Evelo Biosciences Inc.

Insider and Institutional Ownership

Institutional investors held 0% of AnaptysBio Inc. shares and 84.8% of Evelo Biosciences Inc. shares. Insiders held 0.2% of AnaptysBio Inc. shares. Competitively, Evelo Biosciences Inc. has 2.68% of it’s share held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
AnaptysBio Inc. 3.67% -6.45% 6.88% 0.26% -19.19% 13.69%
Evelo Biosciences Inc. -5.39% -4.88% -9.61% -1.74% -50.93% -39.28%

For the past year AnaptysBio Inc. has 13.69% stronger performance while Evelo Biosciences Inc. has -39.28% weaker performance.


AnaptysBio Inc. beats Evelo Biosciences Inc. on 6 of the 9 factors.

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The companyÂ’s proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize an anti-PD-1 antagonist antibody (TSR-042) and an anti-TIM-3 antagonist antibody (TSR-022), which are under clinical development; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 checkpoint agonist antibody (CC-90006) that is in clinical stage. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is based in San Diego, California.

Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815 for patients with psoriasis and atopic dermatitis, rheumatoid arthritis, and ulcerative colitis/crohn's colitis; and EDP1503 for the treatment of colorectal cancer, renal cell carcinoma, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.